RankingsPricing
  1. US-listed companies
  2. Akebia Therapeutics, Inc.
  3. Financials
  4. Operating income

Akebia Therapeutics, Inc.AKBA

Market cap
$438.6M
P/E ratio
SummaryFinancials
Period EndOperating income (Million USD)YoY (%)
Dec 31, 2024-50+9.11%
Dec 31, 2023-46-41.53%
Dec 31, 2022-79-70.18%
Dec 31, 2021-265-29.52%
Dec 31, 2020-376+31.49%
Dec 31, 2019-286+60.69%
Dec 31, 2018-178+122.93%
Dec 31, 2017-80-41.44%
Dec 31, 2016-136+121.84%
Dec 31, 2015-62+62.13%
Dec 31, 2014-38

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)